Electromed Stock Price, News & Analysis

Electromed (NYSE American: ELMD), a leader in airway clearance technologies, reported exceptional financial results for Q4 and FY 2025. The company achieved record quarterly revenue of $17.4 million (up 17.3%) and record annual revenue of $64.0 million (up 17.0%). Q4 net income reached $2.2 million ($0.25 per share), while FY 2025 net income was $7.5 million ($0.85 per share).

The company's direct homecare business grew 14.8% in Q4 and 15.7% annually, supported by 62 field sales employees. Operating income surged 46.8% for the full year to $9.7 million. Electromed maintained a strong financial position with $15.3 million in cash, no debt, and completed a $10.0 million share repurchase during FY 2025. The company was also added to the Russell 2000® and 3000® indexes in June 2025.

Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has scheduled its fiscal 2025 fourth quarter financial results announcement for August 26, 2025, after market close.

Management will host a conference call at 5:00 p.m. Eastern Time on the same day. Investors can join via phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International). A webcast will be available through the company's Investor Relations website.

For those unable to attend live, a replay will be accessible by phone using Access ID 10201085, and through the company's website.

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The conference will take place from August 12-14, 2025 in Boston, MA.

President and CEO Jim Cunniff, along with CFO Brad Nagel, will deliver a presentation on Tuesday, August 12 at 12:30 pm ET. Investors can access the live webcast through the company's Investor Relations website, and institutional investors have the opportunity to request one-on-one meetings through Canaccord Genuity.

Electromed Inc. (ELMD) announced that its President and CEO Jim Cunniff will be presenting at the upcoming Investor Summit Virtual event scheduled for June 10, 2025. The presentation will provide an opportunity for investors to learn more about the company's developments and strategic initiatives. The virtual format allows for broader accessibility and engagement with the investment community.

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, will be added to both the Russell 2000® Index and the Russell 3000® Index effective June 27, 2025. The inclusion comes as part of FTSE Russell's 2025 annual reconstitution, based on preliminary additions announced May 23, 2025.

The Russell 3000 Index encompasses the largest 3,000 U.S. public companies by market cap, while the Russell 2000 Index is its small-cap subset. These indices serve as key benchmarks for institutional investors and index funds, with approximately $10.6 trillion in assets benchmarked against Russell US Indexes.

Electromed (NYSE American: ELMD) reported strong Q3 FY 2025 financial results, marking its tenth consecutive quarter of year-over-year revenue and net income growth. Net revenue increased 13.1% to $15.7 million, with operating income rising 16.2% to $2.1 million. Net income grew to $1.9 million ($0.21 per diluted share), up from $1.5 million ($0.17 per diluted share) year-over-year. The company's direct homecare business saw a 14.8% increase to $14.1 million. Operating cash flow improved to $7.5 million for the nine months ended Q3 FY 2025. The board approved a $5M stock repurchase authorization. As of March 31, 2025, Electromed maintained a strong financial position with $15.2 million in cash, $23.4 million in accounts receivable, and no debt.

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has scheduled its fiscal 2025 third quarter financial results announcement for May 13, 2025.

The company will release its financial results for the quarter ended March 31, 2025, after the stock market closes. Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results.

Investors can participate through:

• Domestic dial-in: (844) 826-3033
• International dial-in: (412) 317-5185
• Live webcast: Available in the Investor Relations section of Electromed's website

For those unable to attend live, a replay will be available via:

• Domestic replay: (844) 512-2921
• International replay: (412) 317-6671
• Replay Access ID: 10199555
• Online replay: Available in the Investor Relations section under Events & Presentations

Electromed (NYSE American: ELMD) has announced its participation in the 15th Annual LD Micro Invitational, scheduled for April 9-10, 2025, at the Westin Grand Central in New York. Jim Cunniff, President and CEO, will present on April 10 at 2:30 PM ET.

The event will showcase 50+ companies and features:

• Registration starting April 9 at 2:00 PM ET
• Keynote presentations
• CBIZ Offices Rooftop happy hour
• Company presentations beginning April 10 at 8:00 AM ET
• LD Micro Moneyball Afterparty at the Knickerbocker Hotel

Interested investors can access the live webcast of the presentation through the event registration link: https://ldinv15.sequireevents.com/

Electromed (NYSE American: ELMD) announced that its board of directors has authorized a new share repurchase program of up to $5.0 million of common stock on March 6, 2025. The company, which specializes in innovative airway clearance technologies, will execute the buyback through various means including open market purchases, private transactions, and block trades, depending on market conditions.

Management will determine the timing and volume of repurchases based on market conditions and other factors. The board will periodically review and may modify the authorization's terms and size. CEO Jim Cunniff stated that this initiative demonstrates confidence in their business strength and commitment to creating shareholder value while maintaining financial flexibility for future growth investments.